Skip to content
Strategic Partnering
News
Contact Us
Strategic Partnering
News
Contact Us
About Us
Our Mission
Leadership
Grants
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
FS2: Kynurenic Acid
AI-001: Antigen-Presenting Cells
University of British Columbia
Products & Pipeline
NHP / Cosmetics Platform
Clinical Program & Pipeline
About Us
Our Mission
Leadership
Grants
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
FS2: Kynurenic Acid
AI-001: Antigen-Presenting Cells
University of British Columbia
Products & Pipeline
NHP / Cosmetics Platform
Clinical Program & Pipeline
About Us
Our Mission
Leadership
Grants
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
FS2: Kynurenic Acid
AI-001: Antigen-Presenting Cells
University of British Columbia
Products & Pipeline
NHP / Cosmetics Platform
Clinical Program & Pipeline
Strategic Partnering
News
Contact Us
About Us
Our Mission
Leadership
Grants
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
FS2: Kynurenic Acid
AI-001: Antigen-Presenting Cells
University of British Columbia
Products & Pipeline
NHP / Cosmetics Platform
Clinical Program & Pipeline
Strategic Partnering
News
Contact Us
BirchBioMed Receives Health Canada Green Light to Start the Last Stage of its Groundbreaking Clinical Program of FS2 to Minimize Scarring from Burns
Press Release - BirchBioMed_Nutrasource CTA for Burn Trial